The IBCSG is one of the world’s leading groups in breast cancer research. The IBCSG pioneers research in combined hormonal therapy and chemotherapy, timing and duration of adjuvant therapies and quality of life of breast cancer patients. The latest generation of clinical trials in the adjuvant setting addresses tailored treatment for subgroups of patients, as we also expand our research into neoadjuvant treatment and therapy for advanced disease. In addition to clinical trials, we conduct extensive programs in translational research, database studies, quality of life and statistical methodology. IBCSG strives to conduct clinical trials at the highest level of knowledge in breast cancer medicine, trial methodology, data handling, and ethical conduct.
The goal of clinical research within IBCSG is to give our patients a longer survival and symptom-free period after primary treatment, and to improve their quality of life. We aim to translate the results of our trials into tailored treatments for individual women depending on the characteristics of their cancer and their menopausal status or age. We serve this purpose by also combining our clinical, molecular and pathological findings in order to contribute to the growing field of translational research.
IBCSG’s dynamic, interactive network consists of other cooperative groups as well as individual centers. We conduct clinical trials with up to 500 participating sites from six continents. Our group motto, “one for all and all for one,” reflects the loyalty that guides the worldwide collaboration between the IBCSG and its participating centers. This spirit has grown on the basis of a friendship amongst a group of dedicated researchers with the singular goal of serving women with breast cancer.
IBCSG plays a key role in disseminating practice-changing trial results to the breast cancer community. We publish the results of our research in high-ranking peer reviewed journals and present at major international conferences.